Details of the Drug Formulation (DFM)
| General Information of DFM (ID: F20004) | |||||
|---|---|---|---|---|---|
| Name | 
         Simethicone 180 mg capsule 
       | 
    ||||
| Company | 
         GlaxoSmithKline 
       | 
    ||||
| Active Pharmaceutical Ingredient (API) | Simethicone | 
        
          API Info
           click to show the detail info of this API
       | 
		|||
| Irritable bowel syndrome | ICD-11: DD91 | Approved | |||
| Drug Inactive Ingredient (DIGs) | |||||
| DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
| E06WYP | DIG Info | Glycerin | Antimicrobial preservative ... | ||
| E04KSN | DIG Info | Hexahydric alcohol | Diluent ... | ||
| E0Q6DQ | DIG Info | Mannitol | Diluent ... | ||
| E0HR5F | DIG Info | Soybean lecithin | Other agent | ||
| E0L0MR | DIG Info | Sunset yellow FCF | Colorant | ||
| E05BSD | DIG Info | Titanium dioxide | Coating agent ... | ||
| E0H2SC | DIG Info | Water | Solvent | ||
| Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
|---|---|---|---|---|---|---|
| Oxidoreductase (ORase) | ||||||
| DBT Name: Albendazole monooxygenase (CYP3A4) | Click to Show/Hide | |||||
| Detailed Information | 
		
          DBT Info
           click to show the detail info of this DBT
		 | 
	|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Soybean lecithin | |||||
| Biological Activity | IC50 = 6.61 mg.mL-1 (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP3A4_HUMAN | |||||
| Potential-driven transporter (PDT) | ||||||
| DBT Name: Solute carrier SLCO2B1 (OATPB) | Click to Show/Hide | |||||
| Detailed Information | 
		
          DBT Info
           click to show the detail info of this DBT
		 | 
	|||||
| Experiment (1) for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Sunset yellow FCF | |||||
| Biological Activity | Inhibition ratio = 54.5 % (tested by experiment) | [2] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | SO2B1_HUMAN | |||||
| Experiment (2) for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Sunset yellow FCF | |||||
| Biological Activity | Ki = 68.4 uM (tested by experiment) | [2] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | SO2B1_HUMAN | |||||
| Experiment (3) for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Sunset yellow FCF | |||||
| Biological Activity | Ki = 74 uM (tested by experiment) | [3] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | SO2B1_HUMAN | |||||
| Transmembrane channel/porin (TC/P) | ||||||
| DBT Name: Glycine receptor alpha-1 (GLRA1) | Click to Show/Hide | |||||
| Detailed Information | 
		
          DBT Info
           click to show the detail info of this DBT
		 | 
	|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Mannitol | |||||
| Biological Activity | EC50 = 12589.25 nM (estimated based on the structural similarity with CHEMBL604608 ) | [4] | ||||
| Structural Similarity | Tanimoto coefficient = 0.804878049 | |||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | GLRA1_HUMAN | |||||
| Other protein families (OPF) | ||||||
| DBT Name: Thrombopoietin receptor (MPL) | Click to Show/Hide | |||||
| Detailed Information | 
		
          DBT Info
           click to show the detail info of this DBT
		 | 
	|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Sunset yellow FCF | |||||
| Biological Activity | EC50 = 3000 nM (estimated based on the structural similarity with CHEMBL122867 ) | [5] | ||||
| Structural Similarity | Tanimoto coefficient = 0.93081761 | |||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | TPOR_HUMAN | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.

